Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232400628> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4232400628 endingPage "19" @default.
- W4232400628 startingPage "11" @default.
- W4232400628 abstract "After completing this course, the reader will be able to: Recognize the reversible and irreversible toxicities associated with the management of newly diagnosed ovarian cancer. Better manage recurrent ovarian cancer. Identify the range of chemotherapeutic options in managing recurrent ovarian cancer. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Recognition of recurrent ovarian cancer as a disease with significant secondary responses and remissions has led to an increase in the need for oncologists to plan for the long-term therapy of patients. However, many of the currently available front-line and salvage agents used in advanced ovarian cancer are associated with cumulative and/or irreversible toxicities that pose challenges in long-term planning. The irreversible effects associated with some of these therapies may render patients less tolerant to subsequent treatments and lead to a cycle of diminishing treatment options with each remission and disease relapse. Additionally, the potential for patients to experience cumulative toxicity must be carefully weighed against the goals of prolonging the disease-free interval and improving patient quality of life. A number of agents are available in the treatment armamentarium (platinum, paclitaxel, gemcitabine, etoposide, liposomal doxorubicin, and topotecan), many, but not all of which are associated with cumulative toxicity. For instance, cumulative neurotoxicity associated with cisplatin as first-line therapy may diminish the option for retreatment with platinum at first relapse. In contrast, the main toxicity associated with topotecan is noncumulative, manageable myelosuppression. In this review, the major toxicities associated with the predominant chemotherapy agents used in advanced ovarian cancer are discussed along with selected management approaches in the context of long-term treatment planning and sequencing." @default.
- W4232400628 created "2022-05-12" @default.
- W4232400628 creator A5038170197 @default.
- W4232400628 date "2002-10-01" @default.
- W4232400628 modified "2023-10-18" @default.
- W4232400628 title "Management of Treatment-Related Toxicity in Advanced Ovarian Cancer" @default.
- W4232400628 doi "https://doi.org/10.1634/theoncologist.7-2004-11" @default.
- W4232400628 hasPublicationYear "2002" @default.
- W4232400628 type Work @default.
- W4232400628 citedByCount "0" @default.
- W4232400628 crossrefType "journal-article" @default.
- W4232400628 hasAuthorship W4232400628A5038170197 @default.
- W4232400628 hasBestOaLocation W42324006281 @default.
- W4232400628 hasConcept C121608353 @default.
- W4232400628 hasConcept C126322002 @default.
- W4232400628 hasConcept C143998085 @default.
- W4232400628 hasConcept C151032500 @default.
- W4232400628 hasConcept C2776694085 @default.
- W4232400628 hasConcept C2777292972 @default.
- W4232400628 hasConcept C2778119113 @default.
- W4232400628 hasConcept C2779134260 @default.
- W4232400628 hasConcept C2780258809 @default.
- W4232400628 hasConcept C2780427987 @default.
- W4232400628 hasConcept C2780775027 @default.
- W4232400628 hasConcept C2781209748 @default.
- W4232400628 hasConcept C29730261 @default.
- W4232400628 hasConcept C71924100 @default.
- W4232400628 hasConceptScore W4232400628C121608353 @default.
- W4232400628 hasConceptScore W4232400628C126322002 @default.
- W4232400628 hasConceptScore W4232400628C143998085 @default.
- W4232400628 hasConceptScore W4232400628C151032500 @default.
- W4232400628 hasConceptScore W4232400628C2776694085 @default.
- W4232400628 hasConceptScore W4232400628C2777292972 @default.
- W4232400628 hasConceptScore W4232400628C2778119113 @default.
- W4232400628 hasConceptScore W4232400628C2779134260 @default.
- W4232400628 hasConceptScore W4232400628C2780258809 @default.
- W4232400628 hasConceptScore W4232400628C2780427987 @default.
- W4232400628 hasConceptScore W4232400628C2780775027 @default.
- W4232400628 hasConceptScore W4232400628C2781209748 @default.
- W4232400628 hasConceptScore W4232400628C29730261 @default.
- W4232400628 hasConceptScore W4232400628C71924100 @default.
- W4232400628 hasIssue "90005" @default.
- W4232400628 hasLocation W42324006281 @default.
- W4232400628 hasOpenAccess W4232400628 @default.
- W4232400628 hasPrimaryLocation W42324006281 @default.
- W4232400628 hasRelatedWork W187925780 @default.
- W4232400628 hasRelatedWork W2059474539 @default.
- W4232400628 hasRelatedWork W2068605752 @default.
- W4232400628 hasRelatedWork W2132854807 @default.
- W4232400628 hasRelatedWork W2161508291 @default.
- W4232400628 hasRelatedWork W2416748277 @default.
- W4232400628 hasRelatedWork W24553618 @default.
- W4232400628 hasRelatedWork W2461409983 @default.
- W4232400628 hasRelatedWork W2471957740 @default.
- W4232400628 hasRelatedWork W2953910641 @default.
- W4232400628 hasVolume "7" @default.
- W4232400628 isParatext "false" @default.
- W4232400628 isRetracted "false" @default.
- W4232400628 workType "article" @default.